TENGION
INNOVATORS
Tengion® is a regenerative medicine company in which they discover and develop medicines such as stem-cell induced products created to help regenerate damaged organs or tissue within the body using its Organ Regeneration Platform™. They do this in consideration of the funding that patients have to spend annually and of complex procedures that may just end in death despite the effort, and in turn make their products more effectively simple. Tengion develops other products that promote a decrease in dialysis in kidney transplants, which also deals with the patients’ own stem cells and evoking the regeneration in the functional kidney tissue to put it back to life. This process also makes the rate of rejection and failures to lessen. Because dialysis is a huge problem in those that are diagnosed with advanced chronic kidney disease and in turn causes many patients to use more money on surgeries and medicine even with the 20% mortality rate, this new product allows patients to spend less money and overall become more secure with their life.
Abiomed® is manufacturer of medical implants, especially total artificial hearts like their AbioCor, the world’s first self-contained replacement heart, and the Impella, the world’s smallest artificial heart pump or ventricular assist device. The AbioCor was initially rejected by the FDA in 2005, but later approved in 2006 due to its limited market. AbioCor is for patients with severe heart failure, and can help extend the patients survivability ranging from several days to several months. Abiomed’s sites for Impella can be found throughout the U.S, almost in every state, and can provide the service of the ventricular assist device.
Vital Therapies® is a biotherapeutic company that focuses on liver failure, especially helping people who have damaged their livers with alcohol abuse. They have a product called the ELAD® System, which is a bioartificial support system that functions outside the body, and helps stabilize and regenerate the liver until liver transplant. The ELAD incorporates human liver cells contained in 4 hollow fiber containers with a power system. Data from the ELAD clinical studies have shown promise in increasing the survival rates of patients who have acute liver failure.
ABIOMED
VITAL THERAPIES
